Abiopharma

Twist Bioscience (TWST) Reports Q3 2022 Financial Results Twist Bioscience (TWST) announced its financial results for the period ending Q3 2022. Key Financial Highlights:

• Revenue: 30974
• Net Income: Not disclosed
• EPS: Not disclosed
• Cash and equivalents: 376249
  • “We are the high quality, low cost leader and as the macroeconomic environment continues to hold uncertainty, Twist’s product offerings are resonating with customers,” said Emily M. Leproust, Ph.D., CEO and co
  • founder of Twist Bioscience. “We continue to see large accounts expanding their footprint while we also focus on diversifying our risk across an increasing number of customers, particularly in biopharma. We entered into our first exclusive option and license agreement for a Twist
  • discovered antibody and continue to build a robust ecosystem for DNA data storage through educational materials, including the most recently published white paper, and by driving toward an interoperable system through the development of industry standards."Dr. Leproust continued, "Moving forward, we plan to launch the Factory of the Future in January 2023, which will facilitate growth across all areas of our business. We are well positioned to take market share in synbio and NGS, deliver new antibody targets for our biopharma customers and advance our efforts in DNA data storage toward our first commercial solution, all while targeting toward adjusted EBITDA breakeven at $300 million annual revenue for the core business."FISCAL 2022 THIRD QUARTER FINANCIAL RESULTS
    • targeting an undisclosed checkpoint inhibitor. •Entered into a collaboration with Ildong Pharmaceutical, Twist’s first collaboration with a South Korea-based company, under which Ildong will license a suite of Twist VHH antibody libraries to use to discover and develop antibodies for applications in immuno-oncology. •Entered into an antibody discovery agreement with Xilio Therapeutics to advance the development of novel immunotherapies. •Hosted a ribbon-cutting ceremony for the new location of Twist Boston, also known as Abveris, in Quincy, MA. •The DNA Data Storage Alliance joined SNIA as a Technology Affiliate group to accelerate its mission to create an interoperable ecosystem for DNA-based data storage solutions. •Participated in panels and presentations at key data storage and industry conferences including Fujifilm’s 12th Annual Global IT Executive Summit, the 2022
    • targeting toward adjusted EBITDA breakeven at $300 million annual revenue for the core business."FISCAL 2022